

11-03-05

1PW

Express Mail No.: ED 933 428 030 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Donald J. KYLE et al.

Confirmation No.: 5149

Application No.: 10/607,563

Group Art Unit: 1614

Filed: June 27, 2003

Examiner: To be assigned

Title: THERAPEUTIC AGENTS USEFUL
FOR TREATING PAIN

Attorney Docket No.: 6750-173-999
(CAM No.: 305158-999171)

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office ("Office") of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **A01-A27**, **B01-B11** and **C01-C34**, which are listed on the accompanying Form PTO-1449 entitled "List of References Cited By Applicant."

Legible copies of references **B01-B11** and **C01-C34** are submitted herewith. Applicants note that Ref. **B11** is a copy of the International Search Report for the counterpart International Application.

Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of references **A01-A27**, being United States patents and published applications, are not submitted herewith but will be submitted if requested by the Office.

No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made. 37 C.F.R. §§1.97(g) and (h).

Applicants request that the Examiner review all the references identified on the attached Form PTO-1449, and that they be made of record in the file history of the above-identified application.

As this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, Applicants estimate that no fee is required. Should a fee be required, the Commissioner is authorized to charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Samuel B. Abrams Esq.
George A. Simel 42,140

Date: November 1, 2005

Samuel B. Abrams

(Reg. No. 30,605)


JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

Enclosures



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.
6750-173-999
(305158-999171)APPLICATION NO
10/607,563

APPLICANT

Donald J. KYLE et al.

FILING DATE

June 27, 2003

GROUP

To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	4,439,606	03/27/1984	Du et al.	544	356	
	A02	4,450,272	05/22/1984	Du et al.	544	357	
	A03	5,039,680	08/13/1991	Imperato et al.	514	304	
	A04	5,075,341	12/24/1991	Mendelson et al.	514	282	
	A05	5,198,459	03/30/1993	Imperato et al.	514	397	
	A06	5,232,934	08/03/1993	Downs	514	345	
	A07	5,430,033	07/04/1995	Cliffe et al.	514	254	
	A08	5,442,064	08/15/1995	Pieper et al.	544	360	
	A09	5,461,047	10/24/1995	Hansen Jr. et al.	514	211	
	A10	5,556,837	09/17/1996	Nestler et al.	514	21	
	A11	5,556,838	09/17/1996	Mayer et al.	514	25	
	A12	5,574,052	11/12/1996	Rose et al.	514	343	
	A13	5,756,504	05/26/1998	Bock et al.	514	252	
	A14	5,762,925	06/09/1998	Sagen	424	93.7	
	A15	5,789,412	08/04/1998	Halazy et al.	514	255	
	A16	5,792,768	08/11/998	Kulagowski et al.	514	252	
	A17	5,792,769	08/11/1998	Lu et al.	514	255	
	A18	6,028,195	02/22/2000	Cho et al.	544	360	
	A19	6,109,269	08/29/2000	Rise et al.	128	898	
	A20	6,204,284	03/20/2001	Beer et al.	514	412	
	A21	6,329,395	12/11/2001	Dugar et al.	514	329	
	A22	6,423,716	07/23/2002	Matsuno et al.	514	252.02	
	A23	US 2002/019389	02/14/2002	Kim et al.	514	213.01	
	A24	US 2003/0153596	08/14/2003	Suh et al.	514	311	
	A25	US 2003/0158188	08/21/2003	Lee et al.	514	228.2	
	A26	US 2003/0158198	08/21/2003	Lee et al.	514	241	
	A27	US 2003/0212140	11/13/2003	Suh et al.	514	575	
	A28						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
/	B01	WO 96/21648	07/18/1996	PCT			
/	B02	WO 98/00402	01/08/1998	PCT			
/	B03	WO 99/07672	01/18/1999	PCT			
/	B04	WO 00/52001	09/08/2000	PCT			

B05	WO 02/05819	01/24/2002	PCT				
B06	WO 03/022809 A2	03/20/2003	PCT				
B07	WO 03/062209 A2	07/31/2003	PCT				
B08	WO 03/068749 A1	08/21/2003	PCT				
B09	NL 7 804 136 A	04/27/1979	Netherlands (w/ English Abstract)			XXX	
B10	EP 1 122 242 A1	08/08/2001	EPC				
B11	Int. Search Report of WO 2004/002983 A3	01/23/2004	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C01	Berkow et al., "The Merck Manual of Medical Information," pp. 345-350, 1997
C02	Berkow et al., "The Merck Manual of Medical Information," pp. 352-355, 1997
C03	Berkow et al., "The Merck Manual of Medical Information," pp. 496-500, 1997
C04	Berkow et al., "The Merck Manual of Medical Information," pp. 525-526, 1997
C05	Berkow et al., "The Merck Manual of Medical Information," pp. 528-530, 1997
C06	Berkow et al., "The Merck Manual of Medical Information," pp. 530-532, 1997
C07	Berkow et al., "The Merck Manual of Medical Information," pp. 631-634, 1997
C08	Chiamulera et al., "Reinforcing and Locomotor Stimulant Effects of Cocaine are Absent in mGluR5 Null Mutant Rice," Nature Neurosci., 4(9):873-874, 2001
C09	Cooke, "Glycopyrrolate in Bladder Dysfunction," SA Medical J., 63:3, 1983
C10	Di Marzo et al., "Endovanilloid Signaling in Pain," Current Opinion in Neurobiology, 12:372-379, 2002
C11	Dogrul et al., "Peripheral and Spinal Antihyperalgesic Activity of SIB-1757, A Metabotropic Glutamate Receptor (mGluR ₅) Antagonist, in Experimental Neuropathic Pain in Rats," Neurosci. Lett., 292(2):115-118, 2000
C12	Foley, "Pain" Cecil Textbook of Medicine, pp. 100-107, 1996
C13	Fundytus et al., "Antisense Oligonucleotide Knockdown of mGluR ₁ Alleviates Hyperalgesia and Allodynia Associated with Chronic Inflammation," Pharmacol., Biochem. & Behavior, 73:401-410, 2002
C14	Fundytus et al., "In vivo Antinociceptive Activity of Anti-Rat mGluR ₁ and mGluR ₅ Antibodies in Rats," NeuroReport, 9:731-735, 1998
C15	Fundytus et al., "Knockdown of Spinal Metabotropic Glutamate Receptor 1 (mGluR ₁) Alleviates Pain and Restores Opioid Efficacy after Nerve Injury in Rats," British J. Pharmacol., 132:354-367, 2001
C16	Fundytus, "Glutamate Receptors and Nociception Implications for the Drug-Treatment of Pain," CNS Drugs, 15:29-58, 2001
C17	Goodman and Gillman's the Pharmaceutical Basis of Therapeutics 506, 901-915 (J. Hardman and L. Limbird Eds., 9 th ed. 1996)
C18	Herzog et al., "Urinary Incontinence: Medical and Psychosocial Aspects," Annu. Rev. Gerontol. Geriatr., 9:74-119, 1989
C19	Kwak et al., "A Capsaicin-Receptor Antagonist, Capsazepine Reduces Inflammation-Induced Hyperalgesic Responses in the Rat: Evidence for an Endogenous Capsaicin-Like Substance," Neurosci., 84:619-626, 1998
C20	Levin et al., "Direct Measurement of the Anticholinergic Activity of a Series of Pharmacological Compounds on the Canine and Rabbit Urinary Bladder," J. Urology, 128:396-398, 1982
C21	Matsuno et al., "Potent and Selective Inhibitors of PGDF Receptor Phosphorylation," J. Medicinal Chem., 45:4513-23, 2002
C22	Meyer et al., "5-(1-Piperazinyl)-1H-1,2,4-triazol-3-amines as Antihypertensive Agents, J. Medicinal Chem., 32:593-7, 1989
C23	Mirakhur et al., "Glycopyrrolate: Pharmacology and Clinical Use," Anaesthesia, 38:1195-1204, 1983
C24	Ohkubo et al., "The Selective Capsaicin Antagonist Capsazepine Abolishes the Antinociceptive Action of Eugenol and Guaiacol," J. Dent. Res., 76(4): April 1997
C25	Ossowska et al., "Blockade of the Metabotropic Glutamate Receptor Subtype 5 (mGluR ₅) Produces Antiparkinsonian-Like Effects in Rats," Neuropharmacol., 41:413-420, 2001
C26	Pan et al., "Soluble Polymer-Supported Synthesis of Arylpiperazines," Tett. Lett., 39:9505-9508 1998
C27	Reid et al., "Synthese und Reaktionem Neuer Thiazol-Und Triazol-Abkömmlinge," Chemische Berichte, 116:(4) 1548, 1983
C26	Resnick, "Urinary Incontinence," Lancet, 346:94-99, 1995
C29	Tataczynska et al., "Potential Anxiolytic- and Antidepressant-Like Effects of MPEP, A Potent, Selective and Systemically Active mGlu ₅ Receptor Antagonist," British J. Pharmacol., 132(7):1423-1430, 2001

	C30	Urban et al., "In Vivo Pharmacology of SDZ 249-665, A Novel, Non-Pungent Capsaicin Analogue," Pain, 89:65-74 2000
	C31	Walker et al., "Metabotropic Glutamate Receptor Subtype 5 (mGlu5) and Nociceptive Function. I. Selective Blockade of mGlu5 Receptors in Models of Acute, Persistent and Chronic Pain," Neuropharmacol., 40:1-9, 2000
	C32	Wein, "Pharmacology of Incontinence," Urologic Clinics of North America, 22(3):557-577, 1995
	C33	Spooren et al., "Novel Allosteric Antagonists Shed Light on mGlu ₅ Receptors and CNS Disorders," Trends Pharmacol. Sci., 22(7):331-337, 2001
	C34	Wu et al., "Multiple Sensory and Functional Effects of Non-Phenolic Aminodimethylene Nonivamide: An Approach To Capsaicin Antagonist," Gen. Pharmac., 27(1):151-158 1996
	C35	

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	